Trial Profile
A comparative, randomized, open-label, multicenter study on the efficacy and safety of switch treatment with aripiprazole in schizophrenic out-patients who are experiencing insufficient efficacy with risperidone and/or safety and tolerability issues, while on risperidone
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Sep 2021
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb; Otsuka Pharmaceutical Development & Commercialization
- 16 Feb 2012 Actual end date (April 2007) added as reported by ClinicalTrials.gov.
- 31 Oct 2007 Status changed from in progress to completed
- 11 Jan 2007 Status change